Base, Switzerland

Johanne Renaud

This inventor holds 1 USPTO granted patent. Top assignee: Merck Frosst Canada & Co.. Active years: 2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Johanne Renaud. Retrieved from https://idiyas.com/inventor/johanne-renaud-rbdw1osq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Johanne Renaud

Introduction

Johanne Renaud is a notable inventor based in Base, Switzerland. He has made significant contributions to the field of biochemistry, particularly in the development of therapeutic agents. His work has led to the creation of a patent that addresses important medical challenges.

Latest Patents

Johanne Renaud holds a patent for "Gamma-ketoacid tetrapeptides as inhibitors of caspase-3." This invention is crucial in the study of apoptosis and has potential applications in treating various diseases.

Career Highlights

Renaud is associated with Merck Frosst Canada & Co., a leading pharmaceutical company. His role there has allowed him to work on innovative projects that aim to improve health outcomes.

Collaborations

Throughout his career, Renaud has collaborated with esteemed colleagues, including Erich L. Grimm and Renee Aspiotis. These partnerships have fostered a creative environment that enhances the development of new ideas and solutions.

Conclusion

Johanne Renaud's contributions to the field of biochemistry through his patent and collaborations highlight his role as an influential inventor. His work continues to inspire advancements in medical research and innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…